Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma

Bibliography

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
   PubMed Web of Science ®Google Scholar
• Altekruse SF, Kosary CL, Krapcho M, et al. editors. SEER cancer statistics review, 1975-2007. National Cancer Institute, Bethesda, MD. Available from: http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, 2013
   Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol 2010;11:29-37
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-85
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30:2946-55
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1782–91
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366(19):1770–81
   PubMed Web of Science ®Google Scholar
• Fayers PM, Palumbo A, Hulin C, et al. European Myeloma Network. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011;118:1239-47
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. VISTA Trial Investigators bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17
   PubMed Web of Science ®Google Scholar
• Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259-66
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012;366:1759-69
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149-57
   PubMed Web of Science ®Google Scholar
• FDA US Food and Drug Administration (FDA). Available from: www.fda.gov/
   Google Scholar
• European Medicines Agency (EMA). Science Medicines Health. Available from: www.ema.europa.eu
   Google Scholar
• Muller GW, Corral LG, Shire MG, et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996;39:3238-40
   PubMed Web of Science ®Google Scholar
• Pomalyst® package insert. Celgene Corp. Pomalyst® Available from: http://www.pomalyst.com/
   Google Scholar
• Latif T, Chauhan N, Khan R, et al. Thalidomide and its analogues in the treatment of Multiple Myeloma. Exp Hematol Onccol 2012;1(1):27
   Google Scholar
• Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6
   PubMed Web of Science ®Google Scholar
• Görgün G, Calabrese E, Soydan E. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010;116(17):3227-37
   PubMed Web of Science ®Google Scholar
• Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Oncogene. 2013 Jan 14. doi: 10.1038/onc.2012.599. [Epub ahead of print]
   Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16
   PubMed Web of Science ®Google Scholar
• Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 2013;54(4):683-7
   PubMed Web of Science ®Google Scholar
• Zhu D, Carrol LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57:1849-59
   PubMed Web of Science ®Google Scholar
• Castelli R, Cannavò A, Conforti F, et al. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacol Immunotoxicol 2012;34(5):740-53
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Naziruddin S, et al. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006;30:849-58
   PubMed Web of Science ®Google Scholar
• Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008;22:1925-32
   PubMed Web of Science ®Google Scholar
• Rieman DJ, McClung HA, Dodds RA, et al. Biosynthesis and processing of cathepsin K in cultured human osteoclasts. Bone 2001;28:282-9
   PubMed Web of Science ®Google Scholar
• Bolzoni M, Storti P, Bonomini S, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol 2013;41(4):387-97
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010;327:1345-50
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-9
   PubMed Web of Science ®Google Scholar
• Schuster SR, Kortuem KM, Zhu YX, et al. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2012;120:194
   Google Scholar
• Hoffmann M, Kasserra C, Reyes J, et al. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol 2013;71(2):489-501
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm
   Google Scholar
• Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22(16):3269-76
   PubMed Web of Science ®Google Scholar
• Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008;141(1):41-51
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013;121:1961-7
   PubMed Web of Science ®Google Scholar
• Richardson PG, Siegel DS, Vij R, et al. Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results [abstract No: 634]. ASH: Blood ASH Meeting; 2011. p. 118
   Google Scholar
• Lacy MQ, Kumar S, LaPlants BR, et al. Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow-up and Factors Predicing Outcome in 345 Patients [abstract No: 201]. ASH: Blood ASH Meeting Abstract; 2012
   Google Scholar
• Lacy MQ, Laumann K, LaPlants BR, et al. Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts over Three Years [abstract no: 3963]. ASH: Blood ASH Meeting Abstract; 2011
   Google Scholar
• Leleu X, Attal M, Bertrand A, et al. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. Blood 2013
   Google Scholar
• Matous JV, Siegel DS, Duong HK, et al. MM-008 : A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With Renal Impairment. [Poster no: 772]. EHA: Haematologica EHA Poster Session; 2013
   Google Scholar
• Matous J, Siegel DS, Duong HK, et al. MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI) [abstract: 8585]. ASCO: J Clin Oncol Abstract; 2013
   Google Scholar
• Dimopolous M, Lacy MQ, Moreau P, et al. Pomalidomide in Combination with Low-Dose dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open LAble Study [abstract No: 6]. ASH: Blood ASH Meeting Abstract; 2012
   Google Scholar
• Larocca A, Montefusco V, Oliva S, et al. Pomalidomide Cyclophosphamide and Prednisone is Active in Lenalidomide Relapsed/Refractory Multiple Myeloma [abstract No: O-5]. IMW: Clinical Lymphoma, Myeloma & Leukemia Meeting Abstract; 2013
   Google Scholar
• Mark TM, Boyer A, Rossi A, et al. ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma [abstract No: 77]. ASH: Blood ASH Meeting Abstract; 2012
   Google Scholar
• Berenson JR, Hilger J, Klein L, et al. Pomalidomide+Pegylated Liposomal Doxorubicin in Relapsed/Refractory Multiple Myeloma [abstract No: P-140]. IMW: Clinical Lymphoma, Myeloma & Leukemia Meeting Abstract; 2013
   Google Scholar
• Baz R, Shain KH, Alsina M, et al. Oral weekly Cyclophosphamide in combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort [abstract No: 4062]. ASH: Blood ASH Meeting Abstract; 2011
   Google Scholar
• Richardson PG, Hofmeister CC, Siegel DS, et al. Ph 1 Trial of Pomalidomide, Bortezomib, and Low-dose Dexamethasone (PVD) in Relapsed and/or Refractory Multiple Myleoma [abstract No: P-178]. IMW: Clinical Lymphoma, Myeloma & Leukemia Meeting Abstract; 2012
   Google Scholar
• Staudmauer E, Shah J, Abonour R, et al. Carfilzomib, Pomalidomide and Dexamethasone (CPomd) for Relapsed/Refractory Multiple Myleoma (RRMMM): A Phase I/II Trial [abstract No: P-250]. IMW: Clinical Lymphoma, Myeloma & Leukemia Meeting Abstract; 2013
   Google Scholar
• Vij R, Richardson PG, Siegel DS, et al. Pomalidomide Plus Low-Dose Dexamethasone (POM+LoDEX) in RRMM: Analyses Based on Prior Therapy and Renal Function [abstract No: P-170]. IMW: Clinical Lymphoma, Myeloma & Leukemia Meeting Abstract; 2013
   Google Scholar
• Weisel KC, Dimopoulos MA, Moreau P, et al. Analysis of MM-003 Patients with Moderate Renal Impairment Using Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) vs. High-Dose Dexamethasone (HiDEX) in Relapsed/Refractory Multiple Myeloma (RRMM). [Poster no: 244]. EHA Haematologica Meeting Abstract; 2013
   Google Scholar
• Weisel KC, Dimopoulos MA, Moreau P, et al. Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI) [abstract no: 8527]. ASCO J Clin Oncol Meeting Abstract; 2013
   Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis. Best Pract Res Clin Haematol 2005;18:709-27
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Baudi F, Laumann K, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012;119:5397-404
   PubMed Web of Science ®Google Scholar
• Madan S, Kumar S. Review: extramedullary disease in multiple myeloma. Clin Adv Hematol Oncol 2009;7:802-4
   PubMedGoogle Scholar
• Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25:906-8
   PubMed Web of Science ®Google Scholar